Adenosine is an endogenous nucleoside with a short half-life that regulates many
physiological functions involving the heart and cardiovascular system. Among the …

Background The efficacy and safety of novel oral anticoagulants (NOACs) compared to the
current guideline‐recommended vitamin K antagonists (VKAs) in atrial fibrillation (AF) …

Background: CYP2C19 loss-of-function (LOF) alleles reduce the effectiveness of clopidogrel
in patients undergoing percutaneous coronary intervention for acute coronary syndrome …

Study Objective To compare the effectiveness and safety of ticagrelor versus prasugrel in
preventing recurrent cardiovascular disease (CVD) and major bleeding events in patients …

Background and Objectives It is unclear whether more potent P2Y12 inhibitors are of benefit
to older patients who are at high risk for both ischemia and bleeding. We conducted an …

Background: Contemporary antiplatelet treatment in acute myocardial infarction (AMI) is
based on one of two P2Y12 receptor inhibitors, prasugrel or ticagrelor. The aim of this study …

Introduction Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor added to aspirin is
considered the standard of care for patients with acute coronary syndrome (ACS) …

Introduction: There have been inconsistent data on the direct comparison of prasugrel and
ticagrelor. This meta-analysis was conducted to summarize the current available evidence …

Objective This article compares the clinical outcomes of clopidogrel and ticagrelor in
patients with acute coronary syndrome (ACS) without cytochrome P450 (CYP) 2C19 loss-of …

Background Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y 12 inhibitors remains a challenge in the management of acute coronary syndrome …